Regitz-Zagrosek V, Fielitz J, Dreysse R, Hildebrandt A G, Fleck E
Innere Medizin/Kardiologie, Virchow-Klinikum, Humboldt Universität, Berlin, Germany.
Cardiovasc Res. 1997 Jul;35(1):99-105. doi: 10.1016/s0008-6363(97)00089-8.
Atrial angiotensin II receptors type 1 (AT1) are downregulated in end-stage human heart failure at mRNA and protein level. The present study investigated whether AT1 ventricular mRNA content was reduced in myocardial biopsies from heart failure patients.
AT1 mRNA was quantitated in right ventricular endomyocardial biopsies from 16 patients with decreased left ventricular function (LVEF 36 +/- 3%) due to dilated cardiomyopathy (DCM) and in biopsies from 12 patients with suspected myocardial disease but normal cardiac function (LVEF 62 +/- 2%). Two biopsies per patient were pooled, RNA was extracted and reverse-transcribed after addition of an AT1 cRNA standard. AT1 standard and wild-type RNA were amplified with the same primers in the same PCR tube. The PCR products were hybridized to a microtiter plate and detected and quantitated by an ELISA system. Glyceraldehyde phosphate dehydrogenase (GAPDH) mRNA was determined in the same samples as AT1 mRNA.
In the biopsies from 16 patients with heart failure, a 68% decrease in AT1 mRNA content was found in comparison with 12 controls (heart failure 94 +/- 15 AT1 mRNA copies/ng RNA; controls 297 +/- 45; P < 0.001). Relating AT1 mRNA content to GAPDH mRNA confirmed the specific decrease in AT1 mRNA (AT1/GAPDH: heart failure 1.3 +/- 0.15; controls 3.4 +/- 0.5; p < 0.002). The best correlation between AT1 mRNA content and clinical parameters was found for right ventricular ejection fraction (r = 0.59, P < 0.01).
The quantitative RT-PCR procedure indicated a loss of ventricular AT1 mRNA in human heart failure which corresponds to the loss of AT1 protein described previously. It may underlie the decrease in AT1 protein expression in human heart failure.
在终末期人类心力衰竭中,心房血管紧张素II 1型受体(AT1)在mRNA和蛋白质水平均下调。本研究调查了心力衰竭患者心肌活检中AT1心室mRNA含量是否降低。
对16例因扩张型心肌病(DCM)导致左心室功能降低(左心室射血分数[LVEF] 36±3%)的患者的右心室心内膜活检组织,以及12例疑似心肌疾病但心功能正常(LVEF 62±2%)的患者的活检组织进行AT1 mRNA定量分析。将每位患者的两份活检组织合并,加入AT1 cRNA标准品后提取RNA并进行逆转录。在同一PCR管中,用相同引物对AT1标准品和野生型RNA进行扩增。PCR产物与微量滴定板杂交,并通过ELISA系统进行检测和定量。在与AT1 mRNA相同的样本中测定甘油醛-3-磷酸脱氢酶(GAPDH)mRNA。
与12例对照相比,16例心力衰竭患者的活检组织中AT1 mRNA含量降低了68%(心力衰竭组:94±15个AT1 mRNA拷贝/ng RNA;对照组:297±45;P<0.001)。将AT1 mRNA含量与GAPDH mRNA相关联,证实了AT1 mRNA的特异性降低(AT1/GAPDH:心力衰竭组1.3±0.15;对照组3.4±0.5;P<0.002)。AT1 mRNA含量与临床参数之间的最佳相关性见于右心室射血分数(r = 0.59,P<0.01)。
定量RT-PCR方法表明,人类心力衰竭中存在心室AT1 mRNA缺失,这与先前描述的AT1蛋白缺失相对应。它可能是人类心力衰竭中AT1蛋白表达降低的基础。